Boothwyn Pharmacy recalls 8 vials of Fluorescein 2% Ophth 3 mL nationwide after a subpotent drug finding. The recall was issued July 9, 2025 and remains active.
Subpotent Drug
Consumers and healthcare providers should stop using this product immediately. Contact Boothwyn Pharmacy LLC or your healthcare provider for guidance. Notification method: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Ophthalmic fluorescein solutions are used during eye exams and procedures to highlight corneal irregularities.
Subpotent drug may fail to provide adequate therapeutic effect during diagnostic or treatment procedures.
This recall is not part of a broader industry pattern.
Consumers and healthcare providers should stop using the product immediately and seek guidance from Boothwyn Pharmacy or a healthcare provider.
FDA enforcement reports and Boothwyn Pharmacy recall communications
Refund or replacement timelines are provided by Boothwyn Pharmacy and may take weeks
Keep recall notice, packaging, and correspondence with Boothwyn Pharmacy for your records
Brand: Boothwyn Pharmacy. Product: Fluorescein 2% Ophth, 3 mL. Quantity: 8 vials. Distribution: U.S. nationwide. Recall date: 2025-07-09. Model: 06092025@23 BUD 09/09/2025.
No injuries or incidents information provided in the notice.
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet instant alerts for recalls that affect you. Free forever.
Boothwyn Pharmacy LLC issued a nationwide recall of 186 vials of Semaglutide 2.5 mg/mL injection, 0.8 mL, on July 9, 2025. The FDA enforcement report classifies the recall as Class II with a high hazard level. Consumers and healthcare providers should stop using the product immediately and follow guidance from Boothwyn Pharmacy or a healthcare provider.
Boothwyn Pharmacy recalls 642 vials of semaglutide 2.5 mg/mL injection sold nationwide in the U.S. The recall cites subpotent drug with Class II designation. Consumers and healthcare providers should stop using the product immediately and contact Boothwyn Pharmacy for guidance.
Boothwyn Pharmacy recalls 648 vials of semaglutide 2.5 mg/mL injection nationwide after detecting subpotent potency. The recall involves products distributed across the U.S. and is classified as Class II with a high hazard level. Stop using the product and contact Boothwyn Pharmacy or a healthcare provider for guidance.